Debiopharm | GenomeWeb

Debiopharm

The firm said that it has completed clinical trials for the Group B Strep assay for the FDA and will start trials for the C. difficile test this month. 

The investment is the second for GenePOC from the Swiss pharmaceutical company, which will also now also manufacture GenePOC consumables in Europe.

Molecular diagnostic sample prep firm Spinomix has received an undisclosed payment from Swiss-based global biopharmaceutical conglomerate Debiopharm Group for achieving a development milestone for a pair of sample prep technologies, Debiopharm said this week.

WaferGen Biosystems has shuffled and reduced the size of its board of directors to seven from nine following the firm's acquisition of IntegenX's next-g

Swiss molecular diagnostics developer Diagnoplex said last week that it has closed a CHF1.3 million ($1.4 million) financing round led by Debiopharm Diagnostics, part of the Swiss-based global biopharmaceutical conglomerate Debiopharm Group.

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.

This article has been updated to include comment from Marina's management.

While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.

Under the terms of the deal, Debiopharm will have “full responsibility for the development and commercialization of any products arising from the partnership,” the companies said.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.